Partial dopamine agonists in the treatment of psychosis

Research output: Contribution to journalArticle

127 Citations (Scopus)

Abstract

The discovery and characterization of dopamine in the mammalian brain earned Dr. Arvid Carlsson the Nobel Prize in 2000. Along with his many insights about dopamine pharmacology, came his proposal of the existence and critical role of dopamine autoreceptors in the overall regulation of dopamine-mediated neurotransmission. In this paper, the rationale, the putative mechanisms, and pertinent clinical data are reviewed to support the idea of the clinical relevance of dopamine agonists, especially partial agonists, in the treatment of psychosis. Evidence was gathered for the usefulness of this strategy in schizophrenia in early trials with apomorphine and N-propylnoraporphine (NPA). But clinical relevance was not a reality before the application of (-)-3PPP. These clinical results are presented. Moreover, now a partial dopamine agonist, aripiprazole, has been developed and will likely be marketed by BMS and Otsuka for the treatment of psychosis and will be the first drug in this class to be commercially available. Partial dopamine agonists represent the next new class of antipsychotic drugs, effective in treating schizophrenia.

Original languageEnglish (US)
Pages (from-to)411-420
Number of pages10
JournalJournal of Neural Transmission
Volume109
Issue number3
DOIs
StatePublished - 2002

Fingerprint

Dopamine Agonists
Psychotic Disorders
Dopamine
Schizophrenia
Nobel Prize
Autoreceptors
Apomorphine
Synaptic Transmission
Antipsychotic Agents
Pharmacology
Brain
Pharmaceutical Preparations

Keywords

  • (-)-3PPP
  • Apomorphine
  • Dopamine
  • N-propylnorapomorphine
  • Schizophrenia

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Partial dopamine agonists in the treatment of psychosis. / Tamminga, C. A.

In: Journal of Neural Transmission, Vol. 109, No. 3, 2002, p. 411-420.

Research output: Contribution to journalArticle

@article{47f915f4225d46028c490cd62b3088e2,
title = "Partial dopamine agonists in the treatment of psychosis",
abstract = "The discovery and characterization of dopamine in the mammalian brain earned Dr. Arvid Carlsson the Nobel Prize in 2000. Along with his many insights about dopamine pharmacology, came his proposal of the existence and critical role of dopamine autoreceptors in the overall regulation of dopamine-mediated neurotransmission. In this paper, the rationale, the putative mechanisms, and pertinent clinical data are reviewed to support the idea of the clinical relevance of dopamine agonists, especially partial agonists, in the treatment of psychosis. Evidence was gathered for the usefulness of this strategy in schizophrenia in early trials with apomorphine and N-propylnoraporphine (NPA). But clinical relevance was not a reality before the application of (-)-3PPP. These clinical results are presented. Moreover, now a partial dopamine agonist, aripiprazole, has been developed and will likely be marketed by BMS and Otsuka for the treatment of psychosis and will be the first drug in this class to be commercially available. Partial dopamine agonists represent the next new class of antipsychotic drugs, effective in treating schizophrenia.",
keywords = "(-)-3PPP, Apomorphine, Dopamine, N-propylnorapomorphine, Schizophrenia",
author = "Tamminga, {C. A.}",
year = "2002",
doi = "10.1007/s007020200033",
language = "English (US)",
volume = "109",
pages = "411--420",
journal = "Journal of Neural Transmission",
issn = "0300-9564",
publisher = "Springer Verlag",
number = "3",

}

TY - JOUR

T1 - Partial dopamine agonists in the treatment of psychosis

AU - Tamminga, C. A.

PY - 2002

Y1 - 2002

N2 - The discovery and characterization of dopamine in the mammalian brain earned Dr. Arvid Carlsson the Nobel Prize in 2000. Along with his many insights about dopamine pharmacology, came his proposal of the existence and critical role of dopamine autoreceptors in the overall regulation of dopamine-mediated neurotransmission. In this paper, the rationale, the putative mechanisms, and pertinent clinical data are reviewed to support the idea of the clinical relevance of dopamine agonists, especially partial agonists, in the treatment of psychosis. Evidence was gathered for the usefulness of this strategy in schizophrenia in early trials with apomorphine and N-propylnoraporphine (NPA). But clinical relevance was not a reality before the application of (-)-3PPP. These clinical results are presented. Moreover, now a partial dopamine agonist, aripiprazole, has been developed and will likely be marketed by BMS and Otsuka for the treatment of psychosis and will be the first drug in this class to be commercially available. Partial dopamine agonists represent the next new class of antipsychotic drugs, effective in treating schizophrenia.

AB - The discovery and characterization of dopamine in the mammalian brain earned Dr. Arvid Carlsson the Nobel Prize in 2000. Along with his many insights about dopamine pharmacology, came his proposal of the existence and critical role of dopamine autoreceptors in the overall regulation of dopamine-mediated neurotransmission. In this paper, the rationale, the putative mechanisms, and pertinent clinical data are reviewed to support the idea of the clinical relevance of dopamine agonists, especially partial agonists, in the treatment of psychosis. Evidence was gathered for the usefulness of this strategy in schizophrenia in early trials with apomorphine and N-propylnoraporphine (NPA). But clinical relevance was not a reality before the application of (-)-3PPP. These clinical results are presented. Moreover, now a partial dopamine agonist, aripiprazole, has been developed and will likely be marketed by BMS and Otsuka for the treatment of psychosis and will be the first drug in this class to be commercially available. Partial dopamine agonists represent the next new class of antipsychotic drugs, effective in treating schizophrenia.

KW - (-)-3PPP

KW - Apomorphine

KW - Dopamine

KW - N-propylnorapomorphine

KW - Schizophrenia

UR - http://www.scopus.com/inward/record.url?scp=0036202379&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036202379&partnerID=8YFLogxK

U2 - 10.1007/s007020200033

DO - 10.1007/s007020200033

M3 - Article

C2 - 11956961

AN - SCOPUS:0036202379

VL - 109

SP - 411

EP - 420

JO - Journal of Neural Transmission

JF - Journal of Neural Transmission

SN - 0300-9564

IS - 3

ER -